• Revelation Biosciences Inc REVB.OQ reported a quarterly adjusted loss of $2.71​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-25.32. The mean expectation of two analysts for the quarter was for a loss of $1.15 per share. Wall Street expected results to range from $-1.55 to -75 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Revelation Biosciences Inc's reported EPS for the quarter was a loss of $2.71​.

• The company reported a quarterly loss of $3.01 million.

• Revelation Biosciences Inc shares had fallen by 15.0% this quarter and lost 68.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Revelation Biosciences Inc is $53.00, about 98.1% above its last closing price of $1.02

This summary was machine generated from LSEG data May 8 at 03:48 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)